Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures

Veterinary and Comparative Oncology

Volumn 12, Issue 3, 2014, Pages 215-226

  Worley, Deanna R ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Lymph node; Metastasis; Surgical oncology

Indexed keywords

ANIMAL; DOG; DOG DISEASES; FEMALE; LYMPH NODE; LYMPHATIC METASTASIS; MASTOCYTOMA; PATHOLOGY; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; VETERINARY;

ANIMALS; DOG DISEASES; DOGS; FEMALE; LYMPH NODES; LYMPHATIC METASTASIS; MASTOCYTOMA; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 84905399187     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2012.00354.x     Document Type: Article

References (51)

1. Giuliano AE, Kirgan DM, Guenther JM and Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Annals of Surgery 1994; 220: 391-398 discussion 398-401.
2. Wong JH, Cagle LA and Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Annals of Surgery 1991; 214: 637-641.
3. Faries MB and Morton DL. Surgery and sentinel lymph node biopsy. Seminars in Oncology 2007; 34: 498-508.
4. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ and Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Archives of Surgery 1992; 127: 392-399.
5. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clinical & Experimental Metastasis 2012; doi: 10.1007/s10585-012-9503-3.
6. Chen SL, Iddings DM, Scheri RP and Bilchik AJ. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA: A Cancer Journal for Clinicians 2006; 56: 292-309 quiz 316-297.
7. Gervasoni JJE, Taneja C, Chung MA and Cady B. Biologic and clinical significance of lymphadenectomy. The Surgical Clinics of North America 2000; 80: 1631-1673.
8. de Boer M, van Dijck JA, Bult P, Borm GF and Tjan-Heijnen VC. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. Journal of the National Cancer Institute 2010; 102: 410-425.
9. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M and Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Annals of Surgery 2010; 252: 426-432 discussion 432-423.
10. Ran S, Volk L, Hall K and Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010; 17: 229-251.
11. th edn., SJ Withrow and DM Vail Eds., St. Louis, Saunders Elsevier, 2007; 402-424.
12. Welle MM, Bley CR, Howard J and Rufenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Veterinary Dermatology 2008; 19: 321-339.
13. Chaffin K and Thrall DE. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Veterinary Radiology & Ultrasound 2002; 43: 392-395.
14. Cahalane AK, Payne S, Barber LG, Duda LE, Henry CJ, Mauldin GE, Frimberger S, Cotter M and Moore AS. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). Journal of the American Veterinary Medical Association 2004; 225: 401-408.
15. Gieger TL, Theon AP, Werner JA, McEntee MC, Rassnick KM and DeCock HE. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). Journal of Veterinary Internal Medicine 2003; 17: 687-692.
16. Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA and Patnaik AK. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 2004; 224: 236-240.
17. Tuohy JL, Milgram J, Worley DR and Dernell WS. A review of sentinel lymph node evaluation and the need for its incorporation into veterinary oncology. Veterinary and Comparative Oncology 2009; 7: 81-91.
18. Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, Fitzgerald SD, Gamble D, Ginn PE, Goldschmidt MH, Hendrick MJ, Howerth EW, Janovitz EB, Langohr I, Lenz SD, Lipscomb TP, Miller MA, Misdorp W, Moroff S, Mullaney TP, Neyens I, O'Toole D, Ramos-Vera J, Scase TJ, Schulman FY, Sledge D, Smedley RC, Smith K, W Snyder P, Southorn E, Stedman NL, Steficek BA, Stromberg PC, Valli VE, Weisbrode SE, Yager J, Heller J and Miller R. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Veterinary Pathology 2011; 48: 147-155.
19. Romansik EM, Reilly CM, Kass PH, Moore PF and London CA. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Veterinary Pathology 2007; 44: 335-341.
20. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH and Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006; 8: 104-111.
21. Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, Hamilton E and Kiupel M. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Veterinary Research 2008; 4: 32.
22. Environment CDoPHa. Radioactive materials license number Colo. 002-19, Amendment No. 66, 2009.
23. Zawieja D. Lymphatic biology and the microcirculation: past, present and future. Microcirculation 2005; 12: 141-150.
24. Krick EL, Billings AP, Shofer FS, Watanabe S and Sorenmo KU. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Veterinary and Comparative Oncology 2009; 7: 130-138.
25. Lawenda BD, Mondry TE and Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA: A Cancer Journal for Clinicians 2009; 59: 8-24.
26. Amersi F and Hansen NM. The benefits and limitations of sentinel lymph node biopsy. Current Treatment Options in Oncology 2006; 7: 141-151.
27. East J, Valentine C, Kanchev E and Blake G. Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surgery 2009; 9: 2.
28. Golshan M and Nakhlis F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? The Breast Journal 2006; 12: 428-430.
29. Cimmino VM, Brown AC, Szocik JF, Pass HA, Moline S, De SK and Domino EF. Allergic reactions to isosulfan blue during sentinel node biopsy--a common event. Surgery 2001; 130: 439-442.
30. Thevarajah S, Huston TL and Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. The American Journal of Surgery 2005; 189: 236-239.
31. Bézu C, Coutant C, Salengro A, Darai E, Rouzier R and Uzan S. Anaphylactic response to blue dye during sentinel lymph node biopsy. Surgical Oncology 2011; 20: e55-e59.
32. Stradling B, Aranha G and Gabram S. Adverse skin lesions after methylene blue injections for sentinel lymph node localization. The American Journal of Surgery 2002; 184: 350-352.
33. Gelb HR, Freeman LJ, Rohleder JJ and Snyder PW. Feasibility of contrast-enhanced ultrasound-guided biopsy of sentinel lymph nodes in dogs. Veterinary Radiology & Ultrasound 2010; 51: 628-633.
34. Nielsen KR. Studies on radionuclide imaging and contrast ultrasound for sentinel node diagnostics in breast cancer and melanoma. Danish Medical Bulletin 2011; 58: B4225.
35. Wisner ER, Ferrara KW, Short RE, Ottoboni TB, Gabe JD and Patel D. Sentinel node detection using contrast-enhanced power Doppler ultrasound lymphography. Investigative Radiology 2003; 38: 358-365.
36. Wisner ER, Ferrara K, Gabe JD, Patel D, Nyland TG, Short RE and Ottoboni TB. Contrast enhanced intermittent power Doppler ultrasound with sub-micron bubbles for sentinel node detection. Academic Radiology 2002; 9(Suppl. 2): S389-391.
37. Kim T, Giuliano AE and Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer 2006; 106: 4-16.
38. Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, Ng PC, Edwards MS, Halliday BE, Henry CA, Sommer LM, Carman CM, Molin MR, Yurko JE, Perry RR and Williams R. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Annals of Surgery 2001; 233: 51-59.
39. Sanidas EE, de Bree E and Tsiftsis DD. How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer? The American Journal of Surgery 2003; 185: 202-210.
40. Posther KE, McCall LM, Blumencranz PW, Burak WE, Beitsch PD, Hansen NM, Morrow M, Wilke LG, Herndon JE 2nd, Hunt KK and Giuliano AE. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Annals of Surgery 2005; 242: 593-599 discussion 599-602.
41. Tuttle TM. Technical advances in sentinel lymph node biopsy for breast cancer. American Surgeon 2004; 70: 407-413.
42. Strzelczyk I and Finlayson C. Sentinel node biopsy: ALARA and other considerations. Health Physics 2004; 86: S31-S34.
43. Miner TJ, Shriver CD, Flicek PR, Miner FC, Jaques DP, Maniscalco-Theberge ME and Krag DN. Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node. Annals of Surgical Oncology 1999; 6: 75-82.
44. Klausen TL, Chakera AH, Friis E, Rank F, Hesse B and Holm S. Radiation doses to staff involved in sentinel node operations for breast cancer. Clinical Physiology and Functional Imaging 2005; 25: 196-202.
45. Morton R, Horton PW, Peet DJ and Kissin MW. Quantitative assessment of the radiation hazards and risks in sentinel node procedures. British Journal of Radiology 2003; 76: 117-122.
46. Morita ET, Chang J and Leong SPL. Principles and controversies in lymphoscintigraphy with emphasis on breast cancer. The Surgical Clinics of North America 2000; 80: 1721-1739.
47. Stratmann SL, McCarty TM and Kuhn JA. Radiation safety with breast sentinel node biopsy. The American Journal of Surgery 1999; 178: 454-457.
48. Michel R and Hofer C. Radiation safety precautions for sentinel lymph node procedures. Health Physics 2004; 86: S35-S37.
49. Seguin B, Leibman NF, Bregazzi VS, Ogilvie GK, Powers BE, Dernell WS, Fettman MJ and Withrow SJ. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). Journal of the American Veterinary Medical Association 2001; 218: 1120-1123.
50. Weisse C, Shofer FS and Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. Journal of the American Animal Hospital Association 2002; 38: 71-73.
51. Leong SP, Nakakura EK, Pollock R, Choti MA, Morton DL, Henner WD, Lal A, Pillai R, Clark OH and Cady B. Unique patterns of metastases in common and rare types of malignancy. Journal of Surgical Oncology 2011; 103: 607-614.